1. Introduction
Ferroptosis is an iron-dependent form of regulated cell death, characterized by dysregulated iron metabolism, lipid peroxidation, and glutathione (GSH) depletion [
1]. In recent years, substantial evidence has established that ferroptosis plays a significant role in the pathogenesis of ulcerative colitis (UC), particularly in relation to intestinal inflammatory responses and intestinal epithelial cell (IEC) damage. Ferroptosis inhibitors (such as Ferrostatin-1, Fer-1) have been shown to significantly alleviate inflammatory responses and intestinal epithelial injury in animal and cellular models [
2,
3,
4]. Furthermore, regulating iron metabolism (e.g., reducing iron load), decreasing lipid peroxidation, and maintenance GSH levels are important therapeutic strategies for mitigating UC symptoms [
5,
6].
Tryptophan, an essential amino acid, has garnered increasing attention for its role in intestinal inflammation, especially in the pathogenesis of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. Gut microbiota in patients with IBD is characterized by a reduction in beneficial bacteria (such as Faecalibacterium and Ruminococcus) and an increase in harmful bacteria. This dysbiosis alters the production of tryptophan metabolites, including a decrease in indole analogs, thereby compromising immune regulatory functions mediated through the aryl hydrocarbon receptor (AhR) pathway [
7,
8,
9]. Activation of AhR induces the production of anti-inflammatory factors like interleukin-22 (IL-22), thus helping to maintain intestinal barrier integrity. A reduction in tryptophan metabolites, such as 3-IAld, may exacerbate the inflammatory state in IBD [
10,
11,
12]. Experimental evidence has shown that modulating tryptophan metabolism, for instance, via Ganoderic acid A, can improve intestinal barrier function and alleviate colonic inflammation, which further supports the protective role of tryptophan metabolites in IBD [
13,
14].
Tryptophan metabolism is critically involved in regulating ferroptosis. Its metabolites can either inhibit or promote ferroptotic processes through multiple mechanisms. Research indicates that tryptophan metabolites like serotonin (5-HT) and 3-hydroxyanthranilic acid (3-HA) can act as radical-trapping antioxidants (RTAs), directly scavenge lipid peroxidation products and thereby inhibit ferroptosis [
15]. Similarly, the tryptophan metabolism enzyme IL4I1 reduces reactive oxygen species (ROS) accumulation by producing indole-3-pyruvate (I3P) and inhibits the ubiquitination and degradation of Nrf2 through binding, which upregulates antioxidant gene expression and subsequently suppresses ferroptosis [
16,
17,
18,
19]. Furthermore, 3-HA can directly bind to ferritin heavy chain (FTH1) and interfere with its interaction with nuclear receptor coactivator 4 (NCOA4), thereby inhibiting ferritinophagy, reducing the release of free iron, and ultimately alleviating ferroptosis [
20]. Conversely, the regulation of tryptophan metabolism can also affect sensitivity to ferroptosis. For instance, tryptophan itself can inhibit ferroptosis by suppressing NCOA4-mediated FTH1 autophagy and stabilizing ferritin levels [
21].
Additionally, the activation of AhR signaling, associated with tryptophan and its metabolites, plays an essential role in inhibiting ferroptosis. This process typically involves the activation of the Nrf2 (nuclear factor erythroid 2-related factor 2) antioxidant pathway. In sepsis-induced acute kidney injury, the AhR agonist FICZ promotes the nuclear translocation of AhR and Nrf2, upregulates the expression of GPX4 and SLC7A11, reduces lipid peroxide accumulation, and thereby inhibits ferroptosis [
22]. In models of doxorubicin-induced cardiomyopathy and ischemic stroke, the microbial metabolite indole-3-lactic acid (ILA), acting as an AhR ligand, inhibits ferroptosis in cardiomyocytes and neurons by activating the AhR/Nrf2 signaling axis and upregulating SLC7A11 and GPX4 [
19,
23]. In lung cancer cells, IDO1 activates the AhR/Nrf2 axis, upregulates SLC7A11, enhances the pentose phosphate pathway (PPP) activity, promotes the generation of NADPH and GSH, and thus confers resistance to Erastin-induced ferroptosis [
24]. Moreover, pharmacological inhibition or genetic ablation of AhR has been shown to enhance Erastin-induced ferroptosis. This mechanism is associated with AhR-mediated transcriptional regulation of solute carrier family genes like SLC7A11, while the endogenous ligand indole-3-pyruvate (I3P) protects cells from ferroptosis in an AhR-dependent manner [
25].
In recent years, microecological preparations, including probiotics, prebiotics, and postbiotics, have attracted increasing attention for their beneficial effects on gastrointestinal inflammation, particularly in the context of IBD [
26]. Probiotics are defined as live microorganisms that confer health benefits on the host and have been extensively studied for their capacity to modulate gut microbiota, enhance intestinal barrier function, and attenuate inflammatory responses [
27,
28]. However, the use of live probiotics in vulnerable populations—such as the elderly, infants, or immunocompromised individuals—raises safety concerns [
28,
29]. In this context, the concept of postbiotics has emerged as a promising alternative. Postbiotics are defined as preparations of inanimate microorganisms and/or their metabolites that confer health benefits to the host [
30]. Compared with live probiotics, postbiotics offer several advantages, including a well-defined chemical composition, extended shelf life, and, most importantly, a superior safety profile for sensitive populations such as the elderly, young children, and immunocompromised individuals [
31].
The fermentation product used in this study, postbiotic Nagqu4580, is a freeze-dried powder derived from the mixed fermentation of multiple probiotic strains, including Streptococcus thermophilus S709, Lacticaseibacillus paracasei L578, and Lacticaseibacillus helveticus L551, followed by high-temperature and high-pressure sterilization. This process inactivates the bacterial cells while preserving their metabolites, such as gamma-aminobutyric acid (GABA), 5-hydroxytryptamine (5-HT), acetic acid, and malic acid. Postbiotic Nagqu4580 exhibits excellent acid resistance and contains a variety of bioactive components [
5,
6]. Given its composition of heat-inactivated bacterial cells and bioactive metabolites, Nagqu4580 qualifies as a postbiotic [
32]. Notably, GABA and 5-HT, both of which are present in postbiotic Nagqu4580, have been shown to modulate gut motility, immune responses, and even host mood via the gut–brain axis [
33,
34,
35,
36]. These properties suggest that postbiotic Nagqu4580 may exert protective effects on intestinal health, making it a promising candidate for the management of UC.
To investigate the ameliorative effect of postbiotic Nagqu4580 on ferroptosis in inflamed epithelial cells in UC, the present study focuses on the following pathway. Postbiotic Nagqu4580 modulates the gut microbiota, which reshapes tryptophan metabolism by increasing beneficial metabolites such as N-acetyltryptophan (NAS) and 5-hydroxyindoleacetic acid (5-HIAA) while decreasing harmful metabolites such as 3-indoxyl sulfate (3-IS). This in turn activates intestinal AhR and Nrf2 signaling, inhibits intestinal epithelial ferroptosis, improves barrier function, and ultimately alleviates UC. This delineates its mechanism of action at the organismal level.
2. Materials and Methods
2.1. Preparation of Postbiotic Nagqu4580
The culture medium is mixed with 10–30 g/L of sodium glutamate, stirred at 55–60 °C for 10–15 min, and then pasteurized at 105–115 °C for 15–20 min. Subsequently, it is fermented with the probiotic, which is composed of 2–5% Streptococcus thermophilus S709, 10–20% Lactobacillus paracasei L578, and 75–88% Lactobacillus helveticus L551, at 37–45 °C for 28–35 h. When the pH reached 4.4–4.6, the mixture was stirred at 100–300 rpm, followed by sterilization treatment, and then vacuum freeze-dried to obtain Nagqu4580 powder. Lot/batch information, QC results, and inactivation confirmation of the prepared Nagqu4580 batch data is provided in the
Supplementary Materials. The Nagqu4580 powder was provided by Shanghai Nature’s Sunshine Health Products Co., Ltd.
2.2. Combined Analysis of the Material Composition in Postbiotic Nagqu4580 by LC-MS/MS Metabolomics
Untargeted metabolomic analysis was performed using liquid chromatography–tandem mass spectrometry (LC-MS/MS). Sample preparation: Approximately 100 mg of postbiotic Nagqu4580 powder was weighed, mixed with 1 mL of methanol, vortexed for 10 min, and centrifuged at 12,000 rpm at 4 °C for 10 min. The supernatant was collected for injection. Chromatographic separation was carried out on a Thermo U3000 system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an ACQUITY Premier HSS T3 column (Waters Corporation, Milford, MA, USA).(2.1 × 100 mm, 1.8 μm) maintained at 45 °C. The mobile phase consisted of 0.1% formic acid in water (A) and methanol (B), with a flow rate of 0.3 mL/min. The gradient elution program was as follows: 0–1 min, 2% B; 1–5.5 min, increase to 100% B; maintain until 14 min; 14.1 min, decrease to 2% B; and re-equilibrate until 16 min. Mass spectrometric detection was conducted on a Q Exactive™ instrument operated in data-dependent acquisition (DDA) mode under both positive and negative ionization. Full-scan MS spectra were acquired at a resolution of 70,000 over the m/z range of 150–1500. The top 10 most intense precursor ions were selected for fragmentation with a resolution of 17,500, using stepped collision energies of 10, 30, and 55 eV. Raw data were processed using MS-DIAL software (version 4.70) for peak extraction, noise removal, deconvolution, and alignment, resulting in a three-dimensional data matrix containing retention time, m/z, and peak area. Metabolite identification was performed by matching the extracted MS features against public databases, including MassBank, ReSpect, and GNPS. The matching tolerances were set as follows: MS1 tolerance, 0.01 Da; MS2 tolerance, 0.05 Da; retention time tolerance, 0.05 min; and identification score cutoff > 80.
2.3. Animals
A total of 40 male C57BL/6 mice, aged 6–8 weeks and weighing 20–22 g, were included in this experiment. The mice utilized in this study were procured from Sibeifu Beijing Biotechnology Co., Ltd. (Beijing, China) and verified to be of specific pathogen-free (SPF) status, exhibiting robust physical health and no underlying diseases prior to the commencement of the experiment. All animals were maintained in a standardized barrier animal facility with controlled environmental conditions, including an ambient temperature of 22 ± 2 °C, relative humidity of 50–60%, and a 12 h light-dark cycle. The mice were housed in ventilated cages, with a maximum of five animals per cage, and were provided with ad libitum access to food and water. Following a 7-day acclimatization period, the formal experimental procedures were initiated. The animal study protocol was approved by the Ethics Committee of Xizang Minzu University (Ethics Approval No.: 2024-101).
2.4. Animal Grouping and Acute UC Modeling
Forty mice were randomly divided into 5 groups according to the random number table method, with 8 mice in each group: control group (NC), DSS group (UC), positive drug 5-ASA group (PC), postbiotic Nagqu4580 low-dose group (UC + NL), and postbiotic Nagqu4580 high-dose group (UC + NH). The sample size of 8 mice per group was determined using a power analysis based on preliminary pilot study data (α = 0.05, β = 0.20, power = 80%), accounting for an anticipated attrition rate of up to 25% during the DSS-induced acute phase to ensure sufficient statistical power for primary outcome analysis. During the experimental period, for the first 10 days, the NC, UC, and PC groups were administered normal water by gavage. Normal saline (0.9% sodium chloride solution) was used as the solvent for the bacterial powder to prepare postbiotic Nagqu4580. According to the “Methods for Evaluation of Health Food Function (2023 Edition)”, the dosages for experimental mice were set as low dose (1 g/kg) and high dose (3 g/kg), corresponding to 10 and 30 times the human dose, respectively. The NL and NH groups were administered postbiotic Nagqu4580 by gavage at doses of 1 g/kg and 3 g/kg, respectively. From day 4 onwards, except for the NC group, drinking water was supplemented with 4% (w/v) dextran sulfate sodium (DSS) solution to induce UC. All experimental procedures strictly adhered to the “3R” principles (Replacement, Reduction, Refinement): (1) Replacement: No non-animal alternatives were available for this in vivo modeling and whole-system efficacy assessment. (2) Reduction: The sample size was minimized through rigorous statistical planning while ensuring test validity. (3) Refinement: All manipulations, including intragastric administration and DSS drinking water replacement, were performed gently and quickly in a quiet environment to reduce unnecessary stress stimulation. Strict predefined humane endpoints were established in advance to avoid excessive animal suffering: (1) continuous body weight loss exceeding 20% of the initial body weight; (2) severe persistent bloody diarrhea, accompanied by obvious lethargy, anorexia and dyskinesia; and (3) extreme mental depression and inability to eat and drink independently. Any animal reaching these endpoints was humanely euthanized immediately via cervical dislocation under deep anesthesia (5% isoflurane) and excluded from subsequent analysis. Meanwhile, the PC group was given 100 mg/kg 5-aminosalicylic acid by gavage, and the UC + NL and UC + NH groups continued gavage at the aforementioned concentrations. On day 17, the mice were euthanized by cervical dislocation. During the acute phase, the disease activity index (DAI) score (body weight, stool consistency, and fecal bleeding) was monitored and recorded daily for all groups of mice, and animal deaths in each group were recorded. At the end of the experiment, the complete colon of each mouse was collected, its length was measured, and photographs were taken. The primary outcome measures of this study were predefined as DAI score and final colon length, which serve as the core quantitative indicators for evaluating UC model severity and the therapeutic efficacy of Nagqu4580 intervention. The secondary outcome measures included histological damage degree, inflammatory factor levels, ferroptosis-related molecular expression, gut microbiota composition, and serum tryptophan metabolite profiles, which were used to explore the potential molecular mechanism of Nagqu4580 alleviating ulcerative colitis.
During the entire experimental period, no accidental death of mice occurred. Individual sample size differences in different detection indicators were caused by standardized sample attrition based on experimental requirements and sample quality control, rather than random loss or data screening. The detailed sample attrition reasons and final valid sample size for each endpoint are as follows: (1) Colon length measurement and DAI score assessment (n = 6 per group): Two mice in each group were excluded because their colon tissues were damaged during material collection and could not meet the morphological measurement standards, and their daily behavioral observation records were incomplete, which failed to meet the data inclusion requirements; (2) Gut microbiota sequencing analysis (n = 5 per group): In addition to the above excluded individuals, one more mouse per group was excluded due to insufficient fecal sample collection and unqualified DNA extraction quality, which could not support subsequent 16S rRNA sequencing analysis; and (3) Histopathological H&E staining (n = 6 per group): To ensure the consistency and representativeness of tissue section staining and microscopic observation, only 6 mice with the most stable modeling status and complete tissue morphology in each group were selected for subsequent histological detection.
2.5. Real-Time Fluorescence Quantitative PCR
Total RNA was isolated using the Total RNA Extraction Kit (Biosharp, Beijing, China)and subsequently converted into cDNA via the Prime Script RT Reagent Kit. RT-qPCR was performed using cDNA as the template, TB Green Premix Ex Taq II as the premix, and the primers shown in
Table 1.
2.6. Hematoxylin–Eosin (H&E) Staining
The fixed tissue was dehydrated, embedded, sectioned, dewaxed, stained with hematoxylin (Sigma Aldrich, Shanghai, China) for 5–10 min, differentiated with 3 s of acid alcohol solution, placed in a weak alkaline blue solution for re-blue, and then stained with eosin (Bomei, Hefei, China) for 3 min. It was then graded alcohol dehydrated, transparent with a clarifying agent, and sealed with neutral resin. The images of the sections were captured using a microscopic imaging system (Motic, Xiamen, China). Histological evaluation was conducted in a blinded manner.
2.7. Enzyme-Linked Immunosorbent Assay (ELISA)
The content of TNF-ɑ, IL-1β, IL-6 and 4-HNE in colon tissues was detected strictly according to the instructions of the ELISA kit (ZCIBio, Shanghai, China). Lipid peroxide MDA in colon tissue and GSH and GSSG content in colon tissue were detected by using the reagent kit (Jiancheng, Nanjing, China), and the GSH/GSSG ratio was calculated.
2.8. Immunofluorescence Staining
After dewaxing and hydration of paraffin sections, antigen retrieval was performed to expose antigenic epitopes. Endogenous peroxidase activity was inhibited using 3% H2O2 (Xilong, Wuhan, China), and non-specific sites were blocked with BSA (Servicebio, Wuhan, China). The first round of immunofluorescence staining was carried out: Incubate the sections with the primary antibody at 4 °C overnight, and then add the corresponding HRP-labeled secondary antibody and detect using the TSA fluorescence signal amplification system (Servicebio, Wuhan, China). For the second round of staining, the sections were subjected to antigen retrieval again to dissociate the first-round primary and secondary antibody complexes. Then, the second primary antibody was added and the operation was the same as that for the first primary antibody. Subsequently, the corresponding secondary antibody was reacted at 37 °C. Finally, nuclei were stained with DAPI (Servicebio, Wuhan, China) as a counterstain and mounted using an anti-fade mounting medium to preserve fluorescence for microscopic observation.
2.9. Western Blot Analysis
Prepare the cell protein extract, separate it by SDS-PAGE electrophoresis, and then transfer it to a PVDF membrane. After blocking, the PVDF membrane was incubated overnight at 4 °C with primary antibodies (GPX4, 1:15,000, ACSL4,1:2000, AhR, 1:2000, Nrf2, 1:2000 and anti-β-actin, 1:50,000) (Abclonal, Wuhan, China) (Huabio, Hangzhou, China) (Proteintech, Wuhan, China) (Affinity, Hangzhou, China). The membranes were washed with PBS three times and incubated with goat anti-Mouse IgG (H + L) secondary antibody (1:8000) (Abclonal, Wuhan, China) for 1 h at room temperature. The detection was performed using Torchlight’s Hypersensitive ECL substrate (Biosharp, Shanghai, China), and the imaging was carried out with the Tanon Fluorescence Image Analysis System (V2.0).
2.10. Metabolomic Analysis of Tryptophan and Its Metabolites in Serum
Serum samples were thawed on ice. Then, 50 μL of serum was mixed with chilled methanol containing internal standards for protein precipitation. After being vortex-mixed, the mixture was incubated on ice and centrifuged at 4 °C. The supernatant was collected and centrifuged again. Subsequently, 100 μL of the supernatant was transferred into an injection vial and temporarily stored at −20 °C until LC-MS/MS analysis. The data acquisition was performed using an ultra-performance liquid chromatography (UPLC) system (ExionLC™ AD, SCIEX, Framingham, MA, USA) coupled with a tandem mass spectrometry (MS/MS) system (QTRAP® 6500+, SCIEX, Framingham, MA, USA). Metabolites were separated on a C18 column with a gradient elution using water and acetonitrile as the mobile phases. Mass spectrometry detection was conducted in both positive and negative electrospray ionization (ESI) modes with collision energy (CE) scanning. Strict quality control (QC) measures were implemented to ensure data reliability: pooled QC samples were prepared by mixing equal volumes of all serum samples, inserting every 10 samples during detection to monitor instrument stability and repeatability. The acquired mass spectrometry data were processed using Analyst 1.6.3 and MultiQuant 3.0.3 software. Standard calibration curves with 8 concentration gradient points were established for each target metabolite, with good linearity (R2 > 0.995) for quantitative calculation. The concentrations of metabolites were calculated based on standard curves, followed by normalization and subsequent statistical analysis. Metabolite identification was confirmed by matching retention time, parent ion mass-to-charge ratio, and characteristic fragment ions with authentic standard references.
2.11. 16S rRNA Gene-Based Gut Microbiota Analysis
Animal feces were collected, and microbial genomic DNA was extracted. After quality assessment by agarose gel electrophoresis and Nanodrop, the bacterial 16S rRNA gene V3-V4 region was amplified using primers 338F and 806R. The PCR products were purified using magnetic beads, quantified, and then used for library construction, followed by another round of purification and quality control. Finally, paired-end sequencing (2 × 250 bp) was performed on the Illumina NovaSeq 6000 platform. Strict sequencing quality control and standard bioinformatics processes were implemented: the minimum sequencing depth per sample was set to 50,000 clean reads to ensure sufficient microbial coverage. All raw sequencing reads were quality-filtered, trimmed, and normalized to uniform read counts for inter-sample comparison. Rarefaction curve analysis was performed to verify the adequacy of sequencing depth and community saturation. Operational taxonomic units (OTUs) were clustered at 97% sequence similarity, and taxonomic annotation was performed against the Silva 138 database. For beta-diversity analysis, Bray–Curtis and weighted UniFrac distance matrices were calculated, and principal coordinate analysis (PCoA) was performed to evaluate microbial community structural differences among groups. Statistical significance of beta-diversity differences was determined by permutational multivariate analysis of variance (PERMANOVA) with 999 permutations. False Discovery Rate (FDR) correction was applied for all multiple comparative analyses of microbial taxa and diversity indices to eliminate false positive results. All raw 16S rRNA sequencing data have been uploaded to the NCBI Sequence Read Archive (SRA) public repository, with the accession number: PRJNA1474718. Subsequent analyses were completed at Shanghai Biotree Biomedical Technology Co., Ltd.
2.12. Statistical Analysis
Data analysis was conducted with SPSS 20.0 and GraphPad Prism 8. Measurement data that passed normality tests are presented as mean ± standard deviation (Mean ± SD). Comparisons of means among multiple groups were performed using one-way analysis of variance (One-Way ANOVA). For all multiple pairwise comparisons after ANOVA, the false discovery rate (FDR) correction was strictly performed. If homogeneity of variance was confirmed, post hoc pairwise comparisons were conducted using the LSD test; if homogeneity of variance was not satisfied, Tamhane’s T2 test was applied instead. A p value < 0.05 was considered statistically significant.
4. Discussion
Ulcerative colitis is a chronic inflammatory bowel disease characterized by disrupted intestinal barrier function, dysregulated immune responses, and oxidative stress-induced epithelial damage. Recent advances have highlighted the complex interplay between programmed cell death pathways—particularly ferroptosis—in the pathogenesis of UC [
37]. Emerging evidence has implicated ferroptosis, a non-apoptotic, iron-dependent form of cell death, in intestinal epithelial cell injury [
13]. In this study, we demonstrated that postbiotic Nagqu4580, a probiotic fermentation product, significantly ameliorates DSS-induced acute colitis in mice by inhibiting intestinal epithelial ferroptosis through the microbiota–tryptophan–AhR/Nrf2 axis.
Our results showed that postbiotic Nagqu4580 treatment dose-dependently alleviated colonic inflammation, restored tight junction protein expression (Claudin-1, ZO-1, Occludin), and reduced inflammatory cytokine levels (TNF-α, IL-1β, IL-6). These findings are consistent with previous reports that targeting ferroptosis and oxidative stress can effectively mitigate UC symptoms. Notably, postbiotic Nagqu4580 suppressed lipid peroxidation markers (MDA, 4-HNE) and restored the GSH/GSSG balance, indicating a potent antioxidant effect. The downregulation of ACSL4 and upregulation of GPX4 further confirmed the inhibition of ferroptosis in colonic epithelial cells, providing direct evidence that the therapeutic effect of postbiotic Nagqu4580 is closely linked to the suppression of this specific cell death pathway [
13].
Furthermore, our study found that postbiotic Nagqu4580 significantly improved DSS-induced gut microbiota dysbiosis, which aligns with current research trends in the field of postbiotics. Numerous studies have shown that modulating the gut microbiota through supplementation with specific probiotics, prebiotics, or postbiotics can effectively promote host health and alleviate intestinal inflammation. For example, a systematic review by Smolinska et al. [
26] indicated that various probiotics, prebiotics, synbiotics, and postbiotics exert protective effects in multiple diseases, including IBD, by promoting the growth of beneficial microorganisms, enhancing the intestinal barrier, and modulating immune responses. Notably, Han et al. [
38] reported that heat-inactivated Bifidobacterium M1-3 postbiotics alleviated DSS-induced colitis in mice by regulating the gut microbiota, promoting tryptophan metabolism, and activating the AhR/IL-22 signaling pathway. Chen et al. [
39] also demonstrated that Lacticaseibacillus paracasei L21 and its heat-inactivated postbiotic preparation improved UC by modulating the gut microbiota, restoring the intestinal barrier, and activating the HIF1α/AhR-IL-22 axis. Collectively, these studies suggest that postbiotics, as a safe and effective alternative strategy, hold broad application prospects in the treatment of UC.
To further elucidate the molecular basis underlying the alleviation of UC by postbiotic Nagqu4580, this study analyzed its chemical composition using LC-MS/MS untargeted metabolomics. The results showed that postbiotic Nagqu4580 contains several bioactive metabolites with well-defined activities, including salvianolic acid B, isosakuranin, and linoleamide. Published studies have demonstrated that these components possess antioxidant, anti-inflammatory, or anti-lipid peroxidation properties, thereby providing a reliable material basis for the therapeutic effects of postbiotic Nagqu4580. Specifically, salvianolic acid B, a major water-soluble component of Salvia miltiorrhiza, has been shown in a DSS-induced mouse colitis model to reduce the disease activity index, alleviate mucosal damage and inflammatory cell infiltration, increase short-chain fatty acid production, and modulate gut microbiota composition, with its mechanism of action closely linked to its antioxidant activity [
40]. Isosakuranin, a natural flavonoid, has been confirmed to exert antioxidant and anti-inflammatory activities, playing a positive role in experimental colitis by downregulating the NF-κB signaling pathway [
41]. Linoleamide, an endocannabinoid-like fatty acid amide, inhibits the NF-κB signaling pathway in mouse RAW264.7 macrophages and exerts significant anti-inflammatory effects [
42]. These metabolites exert anti-inflammatory and antioxidant functions through distinct molecular targets, and their synergistic presence in postbiotic Nagqu4580 provides a compositional explanation for the reliable material basis by which this postbiotic preparation inhibits intestinal epithelial ferroptosis and alleviates DSS-induced colitis.
A key finding of this study is the significant modulation of tryptophan metabolism by postbiotic Nagqu4580. Untargeted and targeted metabolomic analyses revealed that DSS-induced colitis caused a profound perturbation in tryptophan metabolism, which was partially reversed by postbiotic Nagqu4580 treatment. Specifically, postbiotic Nagqu4580 decreased the levels of potentially harmful metabolites like
N-acetyltryptophan and increased the production of beneficial indole derivatives, such as indolebutyric acid and 5-HIAA. The increase in colonic 5-HT content further supports a shift towards the serotonin pathway. Tryptophan metabolites, particularly those derived from the gut microbiota, are known to be potent ligands for the aryl hydrocarbon receptor (AhR), a transcription factor that plays a critical role in intestinal immune regulation and barrier integrity [
43]. The decrease in 3-indoxyl sulfate (3-IS), a microbial-derived uremic toxin, and the increase in 5-HIAA suggest that postbiotic Nagqu4580 may remodel the gut microbiota to favor a protective metabolic profile, redirecting tryptophan away from harmful degradation pathways and towards AhR-activating ligands.
To directly assess the impact of postbiotic Nagqu4580 on gut microbiota, we performed 16S rRNA gene sequencing of fecal samples. Our results demonstrated that postbiotic Nagqu4580 treatment partially reversed DSS-induced gut dysbiosis. Alpha diversity analysis showed that the increased observed features in UC mice were reduced by postbiotic Nagqu4580, though not to normal levels. Beta diversity (PCoA) revealed that treated samples scattered between control and UC groups, indicating a partial restoration of microbial community structure. This heterogeneity in response among postbiotic Nagqu4580-treated mice may be attributed to several factors, including individual variations in initial microbiota composition, differences in the extent of DSS-induced colitis severity, and potential variations in host physiological responses to the postbiotic intervention. Nevertheless, the overall shift toward the NC group suggests a modulatory effect of postbiotic Nagqu4580. At the phylum level, after postbiotic Nagqu4580 intervention, the abundance of Proteobacteria showed a slight increase, and the abundance of Actinobacteria remained essentially unchanged compared to the UC group. This elevation was mainly caused by non-pathogenic genera such as Escherichia, Sphingomonas and Psychrobacter, which are common commensals in the gut and do not induce intestinal inflammation. At the genus level, postbiotic Nagqu4580 significantly restored beneficial bacteria such as Dubosiella and Ligilactobacillus, while reducing pro-inflammatory genera, including Ileibacterium and Allobaculum.
LEfSe analysis further revealed statistically robust taxonomic signatures that distinguished the gut microbiota of control, UC, and postbiotic Nagqu4580-treated groups. In UC mice, pro-inflammatory-associated genera such as Ileibacterium, Allobaculum, and Akkermansia were significantly enriched, consistent with their reported roles in promoting intestinal inflammation. Notably, postbiotic Nagqu4580 intervention led to a marked enrichment of several genera with known anti-inflammatory or barrier-protective potential, including Bacteroides_H, Blautia_A_141780, and Helicobacter_D. Among these, Blautia species have been shown to produce short-chain fatty acids and indole derivatives, which can serve as AhR ligands. Bacteroides strains are also recognized for their tryptophan-metabolizing capacity, generating metabolites that modulate host immune responses. Thus, the LEfSe-identified shifts are not merely compositional but likely functional, directly linking postbiotic Nagqu4580-induced microbial remodeling to the production of AhR-activating tryptophan metabolites. These findings reinforce the concept that postbiotic Nagqu4580 rebalances the gut ecosystem by selectively promoting beneficial, metabolically active taxa, thereby suppressing ferroptosis via the microbiota–tryptophan–AhR/Nrf2 axis. Regrettably, the current study failed to perform quantitative correlation analysis between the relative abundance of these two key genera and the concentrations of intestinal protective tryptophan metabolites, which restricts the direct causal proof linking postbiotic Nagqu4580-mediated microbiota modulation to tryptophan-AhR signaling activation. Future in vitro and in vivo validation, including targeted metabolomics quantification and Spearman correlation calculation, will be carried out to explicitly confirm this microbiota–tryptophan metabolic axis, further clarifying the intermediate regulatory mechanism of postbiotic Nagqu4580.
The activation of the AhR pathway and its crosstalk with the oxidative stress response regulator Nrf2 is a central mechanism linking our observations. Our data demonstrate that postbiotic Nagqu4580 significantly upregulated AhR and Nrf2 expression at both the protein and mRNA levels in colonic tissues. This activation extended to their downstream targets, HO-1 and GPX4, which are critical for combating oxidative stress and lipid peroxidation. Critically, this points to an indirect, host-mediated antioxidant mechanism. The protective effect against oxidative damage is not primarily due to direct radical scavenging by metabolites present in the postbiotic, but rather the result of Nagqu4580 activating the AhR/Nrf2 axis, which in turn upregulates the host’s own enzymatic antioxidant defenses. The co-localization and increased expression of AhR and Nrf2 in colonic epithelial cells, as shown by immunofluorescence, further strengthens this mechanistic link. The intricate crosstalk between AhR and Nrf2 is increasingly recognized as a vital defensive axis in the gut–liver axis, where their combined activation helps maintain intestinal barrier function and mitigate inflammation [
44]. These results align perfectly with a growing body of evidence showing that AhR activation can inhibit ferroptosis. For instance, studies have shown that AhR agonists like FICZ and ILA can protect against ferroptosis in models of kidney injury and stroke by upregulating the Nrf2/GPX4/SLC7A11 axis [
22,
23]. Our findings extend this concept to the context of UC, showing that a complex postbiotic like postbiotic Nagqu4580 can harness this pathway in vivo to protect the intestinal epithelium.
It is noteworthy that while 5-ASA, a first-line UC drug, also upregulated Nrf2 and its target genes, it did not significantly affect AhR mRNA levels. This distinction underscores the unique multimodal mechanism of postbiotic Nagqu4580, which appears to act upstream by modulating microbial metabolism to generate endogenous AhR ligands, thereby triggering a broader and more physiological activation of the AhR/Nrf2 cytoprotective axis. This is consistent with studies showing that the anti-ferroptotic effects of microbial metabolites like ILA are AhR-dependent [
22,
23,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45]. The ability of postbiotic Nagqu4580 to both increase protective metabolites (like 5-HIAA, a potential AhR ligand) and decrease toxic ones (like 3-IS) highlights its potential to holistically restore metabolic homeostasis in the inflamed gut. Therefore, we propose that the core antioxidant mechanism of postbiotic Nagqu4580 is the transcriptional activation of endogenous cytoprotective enzymes via AhR/Nrf2 signaling, a strategy that offers a more sustained and systems-level protection compared to the finite and transient chemical antioxidant activity of its constituent metabolites.
In summary, this study provides evidence that postbiotic Nagqu4580 alleviates UC by inhibiting intestinal epithelial ferroptosis via the microbiota tryptophan AhR/Nrf2 axis. By reshaping tryptophan metabolism toward protective pathways (e.g., NAS and 5-HIAA) and reducing harmful metabolites such as 3-IS, postbiotic Nagqu4580 restores redox balance and barrier function in the inflamed colon. These findings offer new insights into the therapeutic potential of probiotic-derived postbiotics in IBD and support further development of postbiotic Nagqu4580 as a functional food or adjunct therapy for UC.
Despite these promising findings, this study has several limitations. First, while we observed changes in microbiota-related metabolites, direct metagenomic sequencing is needed to confirm the specific shifts in gut microbial composition and function induced by postbiotic Nagqu4580. Second, the causal role of specific tryptophan metabolites in mediating the anti-ferroptotic and AhR-activating effects requires validation through in vitro experiments or in vivo metabolite supplementation studies. Third, the use of conditional knockout mice would help establish the necessity of this pathway in mediating the therapeutic effects of postbiotic Nagqu4580. Notably, although postbiotic Nagqu4580 contains a variety of bioactive metabolites that jointly exert colitis-alleviating effects, the precise functional contribution and independent efficacy of each individual compound to the overall protective phenotype remain unclarified in the current study. It is still unclear which key metabolite dominates the regulation of gut microbiota homeostasis, tryptophan metabolism, and AhR-Nrf2 signaling activation, and the potential synergistic or antagonistic interactions among different metabolites also require further systematic exploration. Future studies should address these points to further elucidate the precise molecular mechanisms and evaluate the translational potential of postbiotic Nagqu4580 for UC treatment.